Neuromodulation News and Research

RSS

Uroplasty to publish 12-month results of its OrBIT Urgent PC Neuromodulation System trial

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted the 12-month results of the OrBIT Trial of its Urgent® PC Neuromodulation System that will be published in the January 2010 print edition of THE JOURNAL OF UROLOGY®.

10 Dec 2009

FDA cleared, non-invasive prescription therapeutic device for NVP now available

PrimaBella™, the only non-invasive prescription therapeutic device cleared by the U.S. Food and Drug Administration (FDA) for the treatment of nausea and vomiting due to pregnancy (NVP), is now available. Providing a non-invasive, drug-free treatment for morning sickness, PrimaBella™ has been proven to be safe for both mother and developing baby and can offer quick relief -- the majority of patients report an immediate improvement in NVP symptoms.

9 Dec 2009

DBS therapy offers hope for epilepsy patients

Long-term data from an investigational study of Deep Brain Stimulation (DBS) Therapy for Epilepsy was released this week by Medtronic, Inc. (NYSE:MDT) at the American Epilepsy Society Meeting (AES) in Boston.

7 Dec 2009

FDA approves St. Jude Medical's Penta surgical lead for neurostimulation therapy

St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.

4 Dec 2009

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

St. Jude Medical, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its next-generation MultiSteering Technology software for Rapid Programmer™, a programming platform used to optimize neurostimulation therapy for chronic pain patients.

4 Dec 2009

Second-quarter fiscal 2010 results announced by Medtronic

Medtronic, Inc. today announced financial results for its second quarter of fiscal year 2010, which ended Oct. 30, 2009.

24 Nov 2009

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

St. Jude Medical, Inc. announced today that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.

18 Nov 2009

Presentations to highlight durability and efficacy of urethral bulking agents

Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.

17 Nov 2009

Medtronic launches an educational campaign to raise awareness of overactive bladder

Medtronic, Inc. today announced the kick-off of an educational campaign aimed at raising awareness among women of overactive bladder (OAB), a serious condition that can severely impact patients’ lives. This new campaign, conducted in partnership with leading patient advocacy groups focused on women’s health will help to raise awareness of the prevalence of bladder control problems and encourage patients to find effective treatment options – including and beyond medications.

13 Nov 2009

Detailed review findings of EMPOWER study to evaluate the Maestro System released

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, today announced preliminary findings from its ongoing detailed review of its EMPOWER™ study, a randomized, double-blind, controlled pivotal study designed to evaluate the safety and efficacy of the Maestro® System in the treatment of obesity.

12 Nov 2009

Third-quarter financial results of Boston Scientific announced

Boston Scientific Corporation today announced financial results for the third quarter ended September 30, 2009, as well as guidance for net sales and earnings per share (EPS) for the fourth quarter and full year 2009.

20 Oct 2009

St. Jude Medical's Brio neurostimulator receives CE Mark approval

St. Jude Medical, Inc. (NYSE:STJ) today announced CE (Conformité Européenne) Mark approval of the Brio™ neurostimulator, the world’s smallest, longest-lasting rechargeable deep brain stimulation (DBS) device for treating the symptoms of Parkinson’s disease. A 67-year-old man who has suffered from Parkinson’s disease for more than 26 years became the first person to be implanted with the Brio neurostimulator.

9 Sep 2009

Neuronetics raises funds to expand sales team for NeuroStar TMS Therapy

New Leaf Venture Partners (NLV Partners) announced today it has led a $30 million Series D financing round in Neuronetics, Inc., maker of NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy® for the treatment of depression.

3 Sep 2009

Medtronic's Q1 financial results announced

Medtronic, Inc. (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2010, which ended July 31, 2009.

25 Aug 2009

Nerve shock implant device may help bladder control in urinary incontinence

For people with urinary incontinence who have run out of options, an electrical device might help, according to a new Cochrane Library review.

14 Apr 2009

St. Jude Medical announces first European patient implants of Libra deep brain stimulation systems for Parkinson’s Disease

St. Jude Medical, Inc. has announced the first patient implants of its Libra deep brain stimulation (DBS) system for treating the symptoms of Parkinson's disease, a progressive neurological disorder that affects a person's control over his or her movements and speech.

29 Mar 2009

Neuromodulation News and Research

Uroplasty to publish 12-month results of its OrBIT Urgent PC Neuromodulation System trial

FDA cleared, non-invasive prescription therapeutic device for NVP now available

DBS therapy offers hope for epilepsy patients

FDA approves St. Jude Medical's Penta surgical lead for neurostimulation therapy

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

Second-quarter fiscal 2010 results announced by Medtronic

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

Presentations to highlight durability and efficacy of urethral bulking agents

Medtronic launches an educational campaign to raise awareness of overactive bladder

Detailed review findings of EMPOWER study to evaluate the Maestro System released

Third-quarter financial results of Boston Scientific announced

St. Jude Medical's Brio neurostimulator receives CE Mark approval

Neuronetics raises funds to expand sales team for NeuroStar TMS Therapy

Medtronic's Q1 financial results announced

Nerve shock implant device may help bladder control in urinary incontinence

St. Jude Medical announces first European patient implants of Libra deep brain stimulation systems for Parkinson’s Disease

Functional Electrical Stimulation may benefit people with Parkinson's

Results of St. Jude Medical deep brain stimulation study presented at APA meeting

St. Jude Medical awarded U.S. patent for neurostimulation therapy for depression

URMC testing new device for Parkinson's

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News